Tenpoint raises $235M to launch FDA-approved presbyopia eye drop
What’s the deal? Tenpoint Therapeutics has raised $235 million to fund the launch of Yuvezzi, an eye drop for presbyopia, a common age-related condition that affects close-up vision. The financing includes an $85 million Series B round and a $150 million term loan from Hercules CapitalDealroom has a profile for this one. Try Dealroom →, as the company prepares for a commercial launch in the second quarter of 2026.
The London-based biotech has its US headquarters in Seattle and is positioning Yuvezzi as its first marketed product. Yuvezzi recently received approval from the US Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom →, clearing the final regulatory hurdle.
Why now? The funding comes just months ahead of Yuvezzi’s planned market debut, when manufacturing, marketing, and distribution costs spike. With regulatory approval secured, Tenpoint is shifting from development to execution.
Presbyopia affects most people over forty, and researchers estimate that 2.1 billion people will live with the condition by 2030. That scale helps explain investors’ willingness to back a late-stage push.
What could go wrong? Commercial execution remains the biggest risk. Even with approval, new eye drops must convince both doctors and patients to switch from existing options, including glasses and contact lenses.
Tenpoint is also taking on debt alongside equity, which raises the stakes if sales ramp more slowly than expected. Any delays in launch or weaker-than-expected uptake could strain cash flow.
The signal: Investors are increasingly backing biotechs at the moment they cross from clinical promise to commercial reality. Large financings that mix equity and debt point to confidence in near-term revenues, but also to a more disciplined market that expects products, not just pipelines.
For eye care, the deal underlines growing interest in therapies for widespread, chronic conditions rather than niche diseases. Scale, not rarity, is becoming the bigger draw.
Sources:
Tenpoint Therapeutics
Business Wire
FinSMEs
Business Journals
Biopharma Dive
Pulse 2.0
Image source:
Eyewire News
J.V.
